Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
Portfolio Pulse from Juan Spínelli
Kaya Holdings, Inc. (OTCQB:KAYS) criticizes the FDA's decision to reject MDMA for PTSD treatment and advocates for psilocybin as an alternative. KAYS operates The Sacred Mushroom, a psilocybin treatment facility in Oregon, and invites those seeking psilocybin therapy. CEO Craig Frank expressed disappointment with the FDA's decision and highlighted the potential benefits of psilocybin therapy, supported by recent studies.
August 14, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kaya Holdings criticizes the FDA's decision to reject MDMA for PTSD treatment and advocates for psilocybin as an alternative. The company operates a psilocybin treatment facility and invites those seeking this therapy.
Kaya Holdings' advocacy for psilocybin as an alternative to MDMA for PTSD treatment positions the company favorably in the emerging psilocybin treatment sector. The FDA's rejection of MDMA may drive more attention and potential clients to KAYS' psilocybin facility, potentially boosting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100